Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Curr Diab Rep. 2018 Oct 20;18(12):134. doi: 10.1007/s11892-018-1116-z.
To summarize current clinical data investigating the link between diabetes and heart failure pathophysiology, the association of glucose control with heart failure, and the impact of current antihyperglycemic drugs on heart failure.
Although heart failure is one of the most prevalent outcomes occurring in real life and cardiovascular outcome trials, insufficient attention was given to this condition in diabetes research over the last decades. With both beneficial and detrimental findings for heart failure hospitalization in the health authority-mandated outcome trials for new antihyperglycemic agents, research on heart failure and its interplay with diabetes mellitus gained momentum. Diabetes mellitus and heart failure are both prevalent and intertwined conditions. While currently available heart failure therapies have a similar degree of effectiveness in patients with and without diabetes, the choice of glucose-lowering agents can substantially affect heart failure-related outcome.
总结目前有关糖尿病与心力衰竭病理生理学关系、血糖控制与心力衰竭关系，以及现有抗高血糖药物对心力衰竭影响的临床研究数据。
尽管心力衰竭是现实生活中最常见的结局之一，也是心血管结局试验中观察到的结局，但过去几十年的糖尿病研究对这一情况重视不够。新的抗高血糖药物的卫生部门规定的结局试验中，心力衰竭住院的有益和有害结果都有，因此，心力衰竭及其与糖尿病相互作用的研究进展迅速。糖尿病和心力衰竭都是常见且相互交织的疾病。虽然目前心力衰竭的治疗方法在有或无糖尿病的患者中具有相似的有效性，但降糖药物的选择会对心力衰竭相关结局产生重大影响。
